Phlecs BV
  • Link to LinkedIn
  • Link to Mail
  • Home
  • Phlecs Blue LED Therapy
    • About Blue LED Therapy
    • Phlecs Devices
    • FAQ
    • UV Fluorescent Lamp EU BAN
  • Home Phototherapy
  • Blue light potential
  • Inflammatory skin conditions
  • Clinical research
    • Blue Light safety and mechanisms of action
    • Inflammatory skin diseases
    • Other potential indications
  • About us
    • The story behind Phlecs
    • Meet the team
    • Contact
  • News
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Safety and efficacy comparison of blue versus red light sources for photodynamic therapy using methyl aminolevulinate in photodamaged skin

August 12, 2019/in Clinical Study/by Randy

Blue and red light have similar efficacy as the light source for MAL-PDT when combined with other light sources.

View abstract

0 0 Randy https://www.phlecs.com/wp-content/uploads/2023/06/Phlecs-logo.png Randy2019-08-12 11:20:532019-08-12 11:20:53Safety and efficacy comparison of blue versus red light sources for photodynamic therapy using methyl aminolevulinate in photodamaged skin

Latest News

  • Phlecs closes funding round for launch of next-generation home-use phototherapy in EuropeNovember 8, 2026 - 11:56 am

    Vlissingen, The Netherlands – November 4, 2026 – Phlecs Light & Health has successfully closed a new funding round to accelerate the development and commercialization of its next-generation home-use phototherapy solution. In the Netherlands, more than 800,000 patients suffer from eczema and psoriasis. Our innovative blue light therapy offers an effective, safe, and convenient treatment […]

  • Phlecs announces a clinical breakthrough in treatment of eczema and secures a grant to develop itsnext-generation deviceJune 2, 2025 - 6:18 pm

    Terneuzen, Nederland29 May 2025 On May 1, 2025, a new study from the Dermatology Clinic in Bad Bentheim, Germany, was presented at the German Dermatology Congress (DDG) in Berlin (abstract in German under number FV02/07 at: https://onlinelibrary.wiley.com/doi/10.1111/ddg.15782_g ). In this prospective pilot study, 150 patients with moderate to severe atopic dermatitis were randomized into three […]

  • Phlecs presents two significant clinical studies demonstrating the effectiveness of its technology in supporting patients with eczema and long COVID.December 3, 2024 - 6:18 pm

    Terneuzen, the NetherlandsDecember 3, 2024 The Medical University of Lodz, Poland’s largest public medical university, recently conducted two studies confirming that full-body blue light therapy is a safe and effective treatment for patients with eczema and post-COVID chronic fatigue. David Aubert, CEO, and Co-founder of Phlecs, commented on these promising results, stating, “These findings are […]

  • Recent clinical findings to aid individuals with eczema and enhance their emotional well-beingSeptember 12, 2023 - 11:22 am

    On World Atopic Eczema Day, Phlecs presents an innovative treatment approach aimed at addressing both the skin condition and the emotional well-being of patients. 

Phlecs

Edisonweg 41
4382 NV Vlissingen

The Netherlands

Pages

  • About Blue LED Therapy
  • Blue LED Therapy Devices
  • Blue light potential
  • Clinical research
    • Blue Light safety and mechanisms of action
    • Inflammatory skin diseases
    • Other potential indications
  • Contact
  • Faq
  • Home
  • Home Phototherapy
  • Inflammatory skin conditions
  • Meet the team
  • News
  • The story behind Phlecs
  • Treatment centers

Latest News

  • Phlecs closes funding round for launch of next-generation home-use phototherapy in EuropeNovember 8, 2026 - 11:56 am
  • Phlecs announces a clinical breakthrough in treatment of eczema and secures a grant to develop itsnext-generation deviceJune 2, 2025 - 6:18 pm
  • Phlecs presents two significant clinical studies demonstrating the effectiveness of its technology in supporting patients with eczema and long COVID.December 3, 2024 - 6:18 pm
© Copyright - Phlecs BV - created by Code Fairies
  • Link to LinkedIn
  • Link to Mail
Link to: Propionibacterium Acnes Susceptibility To Low-Level 449nm Blue Light Photobiomodulation Link to: Propionibacterium Acnes Susceptibility To Low-Level 449nm Blue Light Photobiomodulation Propionibacterium Acnes Susceptibility To Low-Level 449nm Blue Light Photob... Link to: Neonatal Phototherapy: A Novel Therapy to Prevent Allergic Skin Disease for At Least 5 Years Link to: Neonatal Phototherapy: A Novel Therapy to Prevent Allergic Skin Disease for At Least 5 Years Neonatal Phototherapy: A Novel Therapy to Prevent Allergic Skin Disease for...
Scroll to top Scroll to top Scroll to top